| SC 13G/A | 2024-02-14 | Schonfeld Strategic Advisors LLC | Cyclacel Pharmaceuticals, Inc. | 1,900 | 0.2% | EDGAR |
| SC 13G/A | 2024-02-14 | Dellora Investments LP | Cyclacel Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-13 | Altium Capital Management LP | Cyclacel Pharmaceuticals, Inc. | 37,982 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-07 | ACORN BIOVENTURES, L.P. | Cyclacel Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2024-01-10 | Altium Capital Management LP | Cyclacel Pharmaceuticals, Inc. | 82,032 | 8.0% | EDGAR |
| SC 13G | 2024-01-04 | Lind Global Fund II LP | Cyclacel Pharmaceuticals, Inc. | 102,250 | - | EDGAR |
| SC 13G | 2023-02-14 | Schonfeld Strategic Advisors LLC | Cyclacel Pharmaceuticals, Inc. | 770,400 | 6.1% | EDGAR |
| SC 13G/A | 2023-02-13 | Dellora Investments LP | Cyclacel Pharmaceuticals, Inc. | 648,752 | 5.2% | EDGAR |
| SC 13G/A | 2023-02-06 | SPHERA FUNDS MANAGEMENT LTD. | Cyclacel Pharmaceuticals, Inc. | 250,000 | 2.0% | EDGAR |
| SC 13G/A | 2023-01-26 | ACORN BIOVENTURES, L.P. | Cyclacel Pharmaceuticals, Inc. | 2,815,146 | 10.0% | EDGAR |
| SC 13G | 2022-08-22 | Dellora Investments LP | Cyclacel Pharmaceuticals, Inc. | 648,752 | 5.2% | EDGAR |
| SC 13G/A | 2022-02-14 | SPHERA FUNDS MANAGEMENT LTD. | Cyclacel Pharmaceuticals, Inc. | 508,322 | 5.1% | EDGAR |
| SC 13G/A | 2022-02-14 | Ikarian Capital, LLC | Cyclacel Pharmaceuticals, Inc. | 99,422 | 1.0% | EDGAR |
| SC 13G/A | 2022-02-04 | Hudson Bay Capital Management LP | Cyclacel Pharmaceuticals, Inc. | 412,500 | 4.0% | EDGAR |
| SC 13G | 2021-03-18 | SPHERA FUNDS MANAGEMENT LTD. | Cyclacel Pharmaceuticals, Inc. | 506,824 | 6.3% | EDGAR |
| SC 13G/A | 2021-02-16 | CVI Investments, Inc. | Cyclacel Pharmaceuticals, Inc. | 280,981 | 4.9% | EDGAR |
| SC 13G | 2021-02-12 | ACORN BIOVENTURES, L.P. | Cyclacel Pharmaceuticals, Inc. | 2,344,491 | 10.0% | EDGAR |
| SC 13G/A | 2021-02-10 | RENAISSANCE TECHNOLOGIES LLC | Cyclacel Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-02-09 | Hudson Bay Capital Management LP | Cyclacel Pharmaceuticals, Inc. | 412,500 | 7.2% | EDGAR |
| SC 13G | 2021-01-11 | Ikarian Capital, LLC | Cyclacel Pharmaceuticals, Inc. | 400,000 | 8.2% | EDGAR |